文献速递肝病消化道肿瘤与早癌

丙型肝炎直接抗病毒治疗持续病毒学应答后肝细胞癌发生的预测模型

Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.
PubMed 文献 · Aliment Pharmacol Ther · 2021-10-07

本研究基于日本24家医院2209例接受直接抗病毒药物(DAA)治疗并获得持续病毒学应答(SVR)且无肝细胞癌(HCC)病史的丙型肝炎患者,开发并验证了一个HCC发生预测模型。模型纳入基线BMI≥25.0 kg/m2、基线FIB-4指数≥3.25、SVR时白蛋白<4.0 g/dL和SVR时甲胎蛋白≥5.0 ng/mL四个因素,验证集2年灵敏度87.5%、阴性预测值99.7%,3年灵敏度71.4%、阴性预测值98.0%。

要点

  • DAA治疗后SVR的丙肝患者仍需监测HCC发生。
  • 预测模型基于BMI、FIB-4、白蛋白和甲胎蛋白四个因素。
  • 评分2分为最佳截断值,验证集阴性预测值高。

核心结论

  • 联合四个因素的预测模型有助于优化DAA介导SVR后HCC发生的监测策略。

研究设计与样本

  • 多中心回顾性队列研究,纳入日本24家医院2209例接受DAA治疗获得SVR且无HCC病史的丙肝患者,分为训练集1473例和验证集736例。

主要发现

  • 训练集多因素Cox分析显示基线BMI≥25.0 kg/m2(P=0.024)、基线FIB-4指数≥3.25(P=0.001)、SVR时白蛋白<4.0 g/dL(P=0.010)和SVR时甲胎蛋白≥5.0 ng/mL(P=0.006)与HCC发生显著相关。
  • 预测模型评分:FIB-4指数≥3.25计2分,其他三个因素各计1分,总分0-5分。
  • ROC曲线分析确定2分为最佳截断值,将患者分为0-1分和2-5分两组。
  • 验证集2年灵敏度和阴性预测值分别为87.5%和99.7%,3年分别为71.4%和98.0%。

关键数值与推荐

  • 基线BMI≥25.0 kg/m2(P=0.024)。
  • 基线FIB-4指数≥3.25(P=0.001)。
  • SVR时白蛋白<4.0 g/dL(P=0.010)。
  • SVR时甲胎蛋白≥5.0 ng/mL(P=0.006)。
  • 预测模型评分2分为最佳截断值。

临床怎么用

  • 对于DAA治疗后获得SVR的丙肝患者,可使用该评分模型识别HCC高风险个体并制定个体化监测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several factors associated with hepatocellular carcinoma (HCC) occurrence after sustained virological response (SVR) in patients with hepatitis C have been reported. However, few validation studies have been performed in the era of direct-acting anti-virals (DAAs). AIMS: To develop a prediction model for HCC occurrence after DAA-mediated SVR and validate its usefulness. METHODS: We analysed 2209 patients with SVR and without a history of HCC who initiated DAA treatment at 24 Japanese hospitals. These patients were divided into a training set (1473 patients) and a validation set (736 patients). RESULTS: In the training set, multivariate Cox proportional hazards analysis showed that the baseline BMI (≥25.0 kg/m2 , P = 0.024), baseline fibrosis-4 (FIB-4) index (≥3.25, P = 0.001), albumin level at SVR (<4.0 g/dL, P = 0.010) and alpha-foetoprotein level at SVR (≥5.0 ng/mL, P = 0.006) were significantly associated with HCC occurrence. We constructed a prediction model for HCC occurrence with these four factors (2 points were added for the FIB-4 index, and 1 point was added for each of the other three factors). Receiver operating characteristics curve analysis identified a score of 2 as the optimal cut-off value for the prediction model (divided into 0-1 and 2-5). In the validation set, the sensitivity and negative predictive value for HCC occurrence were 87.5% and 99.7%, respectively, at 2 years and 71.4% and 98.0%, respectively, at 3 years. CONCLUSION: A prediction model combining these four factors contributes to an efficient surveillance strategy for HCC occurrence after DAA-mediated SVR.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tahata Y, Sakamori R, Yamada R, et al. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment Pharmacol Ther. 2021. PMID: 34618934. doi:10.1111/apt.16632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。